142 related articles for article (PubMed ID: 31246485)
1. An update on the JR blood group system.
Castilho L
Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
[TBL] [Abstract][Full Text] [Related]
2. A review of the JR blood group system.
Castilho L; Reid ME
Immunohematology; 2013; 29(2):63-8. PubMed ID: 24094238
[TBL] [Abstract][Full Text] [Related]
3. ABCG2 null alleles define the Jr(a-) blood group phenotype.
Zelinski T; Coghlan G; Liu XQ; Reid ME
Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
[TBL] [Abstract][Full Text] [Related]
4. The JR blood group system: identification of alleles that alter expression.
Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
[TBL] [Abstract][Full Text] [Related]
5. A novel ABCG2 variant causing Jr(a-) phenotype.
Kwon SS; Yun YE; Kim NH; Suh EJ; Kim SK; Kim S
Transfusion; 2024 Apr; 64(4):E9-E10. PubMed ID: 38361420
[No Abstract] [Full Text] [Related]
6. The JR blood group system (ISBT 032): molecular characterization of three new null alleles.
Hue-Roye K; Lomas-Francis C; Coghlan G; Zelinski T; Reid ME
Transfusion; 2013 Jul; 53(7):1575-9. PubMed ID: 23066723
[TBL] [Abstract][Full Text] [Related]
7. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
[TBL] [Abstract][Full Text] [Related]
9. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
[TBL] [Abstract][Full Text] [Related]
10. Defining the Jr(a-) phenotype in the Japanese population.
Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Exons 3 through 5 of ABCG2 causes the Jr(a-) phenotype in a West African woman.
Saison C; Cartron JP; Arnaud L
Transfusion; 2015 Nov; 55(11):2766-7. PubMed ID: 26173500
[No Abstract] [Full Text] [Related]
12. Biochemical characterization of Jr(a-) blood type-related ABCG2 variants: Arg147Trp and Ser572Arg disrupt the plasma membrane localization of ABCG2.
Toyoda Y; Matsuo H; Tanaka M; Stiburkova B; Takada T
Transfusion; 2024 Feb; 64(2):412-414. PubMed ID: 38379528
[No Abstract] [Full Text] [Related]
13. A new genetic background for the Jr(a-) blood group phenotype caused by the ABCG2*439T allele encoding a p.Arg147Trp change.
Wieckhusen C; Rink G; Scharberg EA; Rothenberger S; Stürtzel A; Richter E; Bugert P
Transfusion; 2017 Dec; 57(12):3063-3064. PubMed ID: 29106709
[No Abstract] [Full Text] [Related]
14. Generation of a human induced pluripotent stem cell line (YUCMi020-A) from peripheral blood mononuclear cells derived from a female with the Jr(a-) blood type.
Cho YK; Kim HK; Suh EJ; Kim HO; Kim S
Stem Cell Res; 2024 Jun; 77():103434. PubMed ID: 38703667
[TBL] [Abstract][Full Text] [Related]
15. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
[No Abstract] [Full Text] [Related]
16. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
17. Expression levels of ABCG2 on cord red blood cells and study of fetal anemia associated with anti-Jr(a).
Fujita S; Kashiwagi H; Tomimatsu T; Ito S; Mimura K; Kanagawa T; Endo M; Miyoshi T; Okamura Y; Tani Y; Tomiyama Y; Kimura T
Transfusion; 2016 May; 56(5):1171-81. PubMed ID: 26868047
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
19. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Eisenblätter T; Hüwel S; Galla HJ
Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
